Hemab Therapeutics (NASDAQ:COAG) Sets New 1-Year High on Analyst Upgrade

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price hit a new 52-week high during mid-day trading on Monday after HC Wainwright raised their price target on the stock from $40.00 to $52.00. HC Wainwright currently has a buy rating on the stock. Hemab Therapeutics traded as high as $39.74 and last traded at $39.37, with a volume of 41506 shares changing hands. The stock had previously closed at $38.03.

COAG has been the topic of several other research reports. Jefferies Financial Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Finally, Evercore began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.40.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of Hemab Therapeutics stock in a transaction on Tuesday, June 16th. The stock was purchased at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired a total of 2,970,541 shares of company stock valued at $55,459,603 in the last 90 days.

Hemab Therapeutics Price Performance

The company has a fifty day moving average price of $28.51. The firm has a market capitalization of $1.82 billion and a P/E ratio of -1.63.

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.